Bronchiolitis obliterans is the leading cause of morbidity and mortality in the pulmonary transplant population with ≥50% of patients who receive a lung transplant developing the condition within 5 years.
The Committee's recommendation was based on data from the omadacycline global development program that included nearly 2000 adults in three Phase 3 studies.
The recommendation was supported by materials developed from the ALIS New Drug Application (NDA), which included data from the CONVERT study.
Hospitalization risk was also reduced for RA patients who received influenza vaccination.
Inappropriate antibiotic prescriptions were highest among urgent care facilities (45.7%), with emergency departments (24.6%), medical offices (17.0%), and retail clinics (14.4%) following.
Immune priming with seasonal H1N1 viruses earlier in life and egg-adaptation in vaccines can impact antibody responses following influenza vaccination.
Most children who died of pneumococcus and Haemophilus influenzae type b presented with pneumonia.
Advanced diagnostic platforms to identify viruses can help patients with severe lower respiratory tract infections avoid unnecessary diagnostic testing, reduce antibiotic use, and initiate antiviral therapy.
To investigate what impact antibiotic treatment duration has on CAP outcomes, researchers from the Warren Alpert Medical School of Brown University conducted a search of various databases for studies comparing the safety and efficacy of treatment regimens lasting ≤6 days (short) and ≥7 days (long).
Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.
The New Drug Application for baloxavir marboxil is supported by results from the Phase 3 CAPSTONE-1 study (N=1436) which examined the effects of a single dose of baloxavir marboxil vs placebo or oseltamivir 75mg twice daily for 5 days.
Most deaths related to community-acquired pneumonia that occurred at tertiary-case hospitals were not preventable.
Respiratory pathogens were associated with an increased risk for treatment failure in children with asthma exacerbations.
The researchers argued that outpatient antibiotic stewardship efforts must be strengthened to eliminate antibiotic treatment for viral upper respiratory infections and acute bronchitis.
The real-world effectiveness of PCV13 vaccine in preventing hospitalization for vaccine-type community-acquired pneumonia was assessed.
Although clinical presentation was similar in both community-acquired pneumonia and non-pneumonia exacerbations, CRP, glucose, and leukocytes were higher in the former vs the latter.
Early clinical response rates were similar across PORT risk class subgroups in patients with community-acquired bacterial pneumonia when treated with omadacycline or moxifloxacin.
PCV13, marketed as Prevnar 13, was evaluated in a test-negative case-control study in real-world conditions where patients were administered pneumococcal vaccination as advised by their healthcare providers.
The advisory comes early as physicians are currently placing vaccine orders.
In the LEAP 2 study (N=738), patients with moderate CABP received either oral lefamulin 600mg every 12 hours for 5 days or oral moxifloxacin 400mg once daily for 7 days.